Immune checkpoint protein inhibitors, such antibodies against PD-L1 (aka CD274) and PD-1 (aka PDCD1), have shown effectiveness against a large number of cancer types, including melanoma, non-small-cell lung cancer, and renal cancer. Here, PDCD1 is linked to non-small cell lung carcinoma.